Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: (OTCQB: $CBDY) (TSXV: $HVT.V) (CSE: $JANE.C) (TSXV: $PCLO.V) (CSE: $EURO.C)
Delta, Kelowna, BC –August 13, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2019/cannabis-potcasts/08131CBDY-HVT-JANE-PCLO-EURO.asp
Today's podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few early announcements.
But first, Grenco Science, the leader in advanced technology cannabis vaporization, announces a joint venture with Vapium, the award-winning vaporization company and resident of Johnson & Johnson Innovation - JLABS (JLABS), and investee of Canopy Growth. The companies will work together to integrate ground-breaking technologies for the medical cannabis industry under the brand name Accudose. The first-of-its-kind cannabis consumption platform will fill a void in the market for an accurate, dosing protocol that will allow practitioners to prescribe cannabis as medicine, reframing cannabis consumption.
"Grenco Science is excited to partner with Vapium and bring Accudose into our growing portfolio of brand partners. After seeing the technology Vapium created, this was a clear fit for the multi-state model we developed to launch the Gio. This partnership will allow us to introduce a product offering into the medical cannabis industry with the first actual accurate dosing technology which has not yet been seen on the market and will propel Accudose to become a leader in the industry," said Chris Folkerts, CEO and Founder of Grenco Science.
"From the inception of Vapium, our primary focus has always been patient-centric," said Michael Trzecieski, Vapium co-founder and CEO. "We've worked hard to fully consider the medical conditions faced by users and created a revolutionary platform that will empower patients and practitioners and we are thrilled to be launching this with Grenco so that the world will benefit. Grenco's multi state filling ecosystem coupled with their international brand recognition is nothing short of remarkable. Combining this infrastructure with our years of medical research, dosing and analytic capabilities, we are uniquely positioned to drive the transparency and efficacy needed to standardize cannabis as medicine."
Under the terms of the partnership, the parties will integrate Vapium's innovative dose control technologies and hardware with new cannabis products from Grenco Science's diverse portfolio of brand partners, which include Caliva, Eaze, FlowerOne, Harvest Health and Old Pal among others, to bring to market the revolutionary, accurate dose-metered cannabis consumption platform.
Target Group Inc. (OTCQB: CBDY) announced that effective August 8, 2019, it has entered into an exclusive licensing, manufacturing and distribution agreement with cGreen Inc. for a period of 10 years. The agreement permits Target Group to manufacture and distribute the patent-pending THC antidote, True Focus™, in the United States, Europe and the Caribbean.
The exclusive licensing agreement grants Target Group the rights to the complete True Focus™ intellectual property portfolio, including use of the "True Focus™" trade name, trademarks, logos and art, rights to product formulations, methods and processes. The agreement will facilitate the expansion of Target Group's growing wellness portfolio and position the Company for global manufacturing and distribution.
Excessive cannabis consumption may lead to adverse and unwanted side effects. True Focus' all-natural, nutraceutical formulation offers a unique solution to rapidly alleviate the undesirable effects associated with over-consumption of tetrahydrocannabinol ("THC"). True Focus' innovative THC antidote is dispensed sublingually via a discreet, pocket-sized spray bottle. True Focus' product formulations are considered 'patent-pending' by way of a United States Patent and Trademark Office ("USPTO") application.
"The True Focus agreement will enable Target Group to enter legal, international markets around the globe, and to develop a centralized distribution channel for its suite of wellness products. This partnership also accelerates Target Group's ability to generate revenue within the broader American, European and Caribbean markets immediately", said Rubin Schindermann, Chief Executive Officer for Target Group.
Harvest One Inc. (TSXV: HVT) (OTCQX: HRVOF), through its wholly-owned subsidiary Satipharm Ltd. today announced positive results of a Phase 2 clinical trial of its CBD GelPell® capsules in the management of Treatment Resistant Epilepsy (TRE) have been published in Epilepsy & Behaviour, a bimonthly peer-reviewed medical journal covering behavioral aspects of epilepsy.
Some of the highlights included:
● Phase 2 open label clinical trial is aimed at measuring safety and efficacy of Satipharm CBD capsules for reducing seizure frequency in children with refractory, or treatment-resistant, epilepsy
● The median reduction of monthly seizures was -82% in the 12-week treatment period in treatment-resistant children when added to current medications
● 56% who started the treatment had a reduction of at least 50% in total number of seizures during the entire treatment period, compared to observation
● 73% were rated as "very much improved/improved" in overall condition on the Caregiver Global Impression of Improvement scale
● 82% were rated as "very much reduced/reduced"
● A mean 73.4% reduction from baseline monthly seizure frequencies was observed
● Two patients were fully seizure-free within 5 weeks of treatment
● An additional seven patients reported >50% seizure frequency reduction
A fulsome description of the study and results can be found in the Harvest One background document available on our website at https://www.harvestone.com/portfolio/satipharm/#clinical-trials
"The results of our second stage of clinical trials on our Satipharm 50mg CBD GelPell® products are very encouraging for the patients we serve, our shareholders and our company" said Grant Froese, Chief Executive Officer of Harvest One. "We continue to be focused on the best in class health, wellness, and self-care products at Harvest One and we believe that our unique products, including the proprietary GelPell®, will be highly sought after as cannabis legalization takes hold around the world".
GelPell® capsules contain full spectrum hemp extract CBD in a seamless gelatine bead. This bead is placed inside a hard gastro-resistant capsule ensuring the release of CBD in the small intestine where it has the greatest effect. Manufactured in Switzerland and EU GMP Certified, every 50mg GelPell® capsule has been clinically proven to improve the body's absorption of CBD and other cannabinoids. They are easy to take and contain a consistent and precise dose of CBD.
"The efficacy of Satipharm's CBD capsules as an add-on therapy in the treatment of pediatric, intractable epilepsy has been shown. Moreover, these results compare favourably to other similar studies of cannabidiol" said Prof. Uri Kramer, Director of Pediatric Epilepsy Service, Tel Aviv Sourasky Medical Centre and Principal Investigator of the trial. "Importantly, the significant reductions in seizure frequency while demonstrating satisfactory safety and tolerability profile, in these very difficult to treat patients, have the potential to be a life-altering event for these patients and their families. I would be greatly interested in prescribing such standardized and clinically tested product as Satipharm's 50mg CBD GelPell®".
Mojave Jane Brands (CSE: JANE) (OTC: HHPHF), a California cannabis company, announced that it is entering the market for cannabis-infused beverages by signing a Manufacturing License Agreement with Vancouver-based HAI Beverages Inc.
The Agreement allows Mojave Jane to exclusively license HAI's proprietary technology for the solubility and bioavailability of THC and CBD components in the State of California. The Company will use this technology in the formation process of flavorless distillates and concentrates produced specifically for non-alcoholic beverage products as a micro-dosage offering.
Advantages of HAI's proprietary technology:
● Allows the body to absorb THC and CBD components immediately, producing desired effects in a matter of minutes and enabling a much better control of dosages both for wellness and recreational purposes.
● Enables precise and predictable dosages.
● While producing a similar effect as an alcoholic beverage, a 12 oz micro-dosed drink, for example, can be enjoyed without negative side effects such as feeling hungover, causing liver damage, ingesting empty calories or remaining in the system for extended periods at a time.
● Neutral in taste for versatile applications.
● Bio-available concentrates in CBD or THC formulation.
Mojave Jane's CEO Gary Latham comments:
"While this is a big step in the evolution of cannabis products for recreational and wellness consumers, it is an even bigger move for Mojave Jane as we now enter California's massive beverage market. The license also allows us to produce an "additive" that can be marketed to other beverage producers, expanding this opportunity to the State's even larger adult beverage market.”
“We truly recognize this Agreement with HAI as an ideal match: The flexibility of HAI's technology lets us manufacture products that create custom effects catering to the specific needs of various consumer demographics. From HAI's perspective, they gain access to the California cannabis and adult beverage market since ingestible CBD and THC products based on their technology can only be produced in a licensed cannabis manufacturing facility like ours. I am looking forward to working with the HAI team on the integration process and as we explore the enormous potential of this opportunity together."
PharmaCielo Ltd. (TSXV:PCLO) (OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced it has signed a sales agreement with Uruguay-based Laboratorios Adler. According to the agreement, PharmaCielo will provide Adler with bulk CBD extracts, bulk and bottled CBD oils and veterinary products that will be sold by Adler in Uruguay, Paraguay, Bolivia and Southern Brazil.
The four-and-a-half-year agreement with option for renewal signals PharmaCielo's foray into the high-growth veterinary CBD treatment and wellness market. This is also the first collaboration between PharmaCielo and Creso Pharma that includes sub-contracting to Creso the responsibility for manufacture and supply of Creso's veterinary feed products, anibidiol® 2.5 and anibidiol® 8, with export approval received from the Swiss Cantonal regulator.
"This exciting entry into the animal health marketplace through the agreement with Adler is an example of PharmaCielo executing on its strategic objectives to supply both bulk oil and proprietary products to customers using established large chain distributors," said David Attard, CEO with PharmaCielo Ltd. "Including Creso Pharma's animal health products also demonstrates both the mutual strategic value of our Creso acquisition proposal, which will be fully realized upon completion of the transaction, and the value of branded, fully manufactured product to provide enhanced margin opportunity. We are thrilled about the potential this agreement brings to all parties, and we look forward to working with our Latin American and European partners."
A manufacturer and importer of products for animal treatment, Laboratorios Adler services a wide range of customers from pet shops to veterinary clinics and wholesale distributors of veterinary products. The CBD-based products that Adler will distribute in its area are designed for trauma pain and cancer-related pain treatment for domestic and large animals.
"We are seeing increased demand for CBD-based veterinary products across all our markets as customers look for natural solutions to address pain, stress and a variety of other ailments in both domestic and large animals," said Adriana Adler, Chief Financial Officer with Laboratories Adler S.A. "Partnering with PharmaCielo gives us an incredible advantage in this rapidly developing category. Creso Pharma's anibidiol® line of products, targeting stress, behavioral problems and chronic pain, along with PharmaCielo's CBD isolate, among the purest and highest quality we've seen, make a great addition to our product portfolio."
EuroLife Brands Inc. (formerly Cannvas MedTech Inc.) (CSE: EURO) (OTCPK: CANVF), a leading digital cannabis education and analytics company, announced that, further to its news release of July 31, 2019, it has completed its name change from "Cannvas MedTech Inc." to "EuroLife Brands Inc." to better reflect the direction of the Company's business.
"We are tremendously excited to complete our company rebrand and continue to leverage our unbiased cannabis education resources to better support the global cannabis community and bring additional value to our shareholders," said Steve Loutskou, Chief Operating Officer, Global Markets, EuroLife Brands. "We are confident that coupling our cannabis education with an exclusive CPG marketplace for discerning cannabis consumers across Europe and South America will meet and exceed their expectations of product selection and overall awareness."
The Company's trading symbol on the Canadian Securities Exchange (the "CSE") has changed to "EURO" and, on the OTC Pink Sheets (the "OTCPK"), remain "CANVF" until the pending symbol change has been approved. The trading symbol will remain as "3CM" on the Frankfurt Stock Exchange. The Company's new CUSIP number for its common shares is 29876F106 and ISIN is CA29876F1062.
The Company has been advised by the CSE that the common shares will commence trading under the new name, effective at the opening of trading on August 14, 2019. In the coming days, all the Company's digital properties will be updated to reflect new EuroLife branding.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment